Citation
Afghahi, Anosheh; Mathur, Maya B.; Thompson, Caroline A.; Mitani, Aya; Rigdon, Joseph; Desai, Manisha; Yu, Peter P.; de Bruin, Monique A.; Seto, Tina; & Olson, Cliff, et al. (2016). Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data across Two Health Care Systems. Journal of Oncology Practice, 12(6), e697-709. PMCID: PMC4957259Abstract
PURPOSE: The 21-gene recurrence score (RS) identifies patients with breast cancer who derive little benefit from chemotherapy; it may reduce unwarranted variability in the use of chemotherapy. We tested whether the use of RS seems to guide chemotherapy receipt across different cancer care settings.METHODS: We developed a retrospective cohort of patients with breast cancer by using electronic medical record data from Stanford University (hereafter University) and Palo Alto Medical Foundation (hereafter Community) linked with demographic and staging data from the California Cancer Registry and RS results from the testing laboratory (Genomic Health Inc., Redwood City, CA). Multivariable analysis was performed to identify predictors of RS and chemotherapy use.
RESULTS: In all, 10,125 patients with breast cancer were diagnosed in the University or Community systems from 2005 to 2011; 2,418 (23.9%) met RS guidelines criteria, of whom 15.6% received RS. RS was less often used for patients with involved lymph nodes, higher tumor grade, and age < 40 or
URL
http://dx.doi.org/10.1200/jop.2015.009803Reference Type
Journal ArticleYear Published
2016Journal Title
Journal of Oncology PracticeAuthor(s)
Afghahi, AnoshehMathur, Maya B.
Thompson, Caroline A.
Mitani, Aya
Rigdon, Joseph
Desai, Manisha
Yu, Peter P.
de Bruin, Monique A.
Seto, Tina
Olson, Cliff
Kenkare, Pragati
Gomez, Scarlett L.
Das, Amar K.
Luft, Harold S.
Sledge, George W., Jr.
Sing, Amy P.
Kurian, Allison W.